Thursday, November 19, 2026
Katherine Stapp
- Edible vaccines and spermicide made from plants that contain human genes could someday save lives and help prevent overpopulation, but watchdog groups are worried about the repercussions if genetic material from these crops gets loose in the food chain.
Animals like mice and gerbils typically have been used to produce human antibodies – proteins that fight disease – but the refining process in vats called “bioreactors” is still expensive and inefficient, and is vulnerable to viral and bacterial contamination.
Some scientists see greater promise in plants, which are not affected by human diseases and could produce antibodies at costs up to 100 times less than traditional cell fermentation.
Several companies are growing crops that have been engineered to produce human antibodies to diseases like Hepatitis B and malaria – or even to sperm, in what the press has dubbed “contraceptive corn.”
The San Diego-based company Epicyte hopes to begin clinical trials of a topical spermicide made from genetically modified (GMO) corn this year. It currently has one crop growing in a greenhouse in the U.S. state of Indiana and a second stage is planned in Hawaii, said Sandy Strauss, Epicyte’s spokesperson.
“We’re following all the (federal) guidelines,” Strauss said. “The chance is almost nil (that there would be inadvertent cross- pollination), but I can’t say 100 percent, because one never knows.”
This is exactly what makes environmental groups like Greenpeace nervous.
“There has been reportage of widespread contamination (by GMO crops) in Mexico and that was something that was predicted could never happen – and it’s happened to a rather extreme degree,” said Craig Culp, the GMO media coordinator for Greenpeace.
The contraceptive corn is not yet in open field trials, which is usually the point at which Greenpeace actively opposes such experimental research. Last September, the group staged a protest in California, where a company was growing rice outdoors that had been spliced with human genes. Greenpeace says some 20 companies worldwide are engaged in this kind of “pharming.”
“We are very much aware of this,” Culp said of the contraceptive corn. “It’s a pretty terrifying scenario that this could get into regular corn and end up in someone’s cornflakes.”
“Open field trials are inherently a danger to the natural environment. Buffer zones (a barrier of regular crops surrounding the GM crops) are absolutely insufficient,” he added. “Even if they’re miles wide, there’s simply no way to contain it; genetic material can be carried by the wind, pollen, insects, seed matter, animal faeces and birds. There are lots of ways this genetic material can escape contained zones.”
The technology, termed “plantibodies” by Epicyte, has a long way to go before hitting the market. Some experts caution it is too early to judge its usefulness or the hazards it may present.
“Biotech has changed the way we think about plants,” said Michael Rodemeyer, executive director of the Washington-based Pew Initiative on Food and Biotechnology, an independent research group that takes a neutral position on biotechnology.
“Corn is a wonderful protein factory that could be of value for pharmaceuticals, diagnostics, and industrial applications,” Rodemeyer said. “Plants are a renewable resource, with environmental and energy advantages. This technology may offer a way to do things that couldn’t be done otherwise.”
Still, he said, “as we’ve seen with the Starlink case, there are concerns that genetic traits could drift to other organisms.”
In 2000, a brand of GMO corn known as Starlink that had only been approved for animal feed somehow found its way into numerous food products in the United States, including taco shells and tortilla chips. Allegations that Starlink caused allergic reactions in some people prompted more than 300 product recalls and raised questions about the efficacy of government regulation of GMO products.
“The question is how do we make sure that the (GMO) versions – particularly for non-food uses – do not get into the food crops, and that’s something the regulatory agencies here are looking at,” Rodemeyer said.
Gene Laos, the chief executive of a Texas-based company called Prodigene that is experimenting with plant-based vaccines, said its cost-effectiveness could be a boon for poorer countries.
“It will definitely benefit the underdeveloped countries, since the carrier for the antigen would be a seed,” he said. “Although edible vaccines have to be administered by a doctor, other factors – transportation, refrigeration – are negated for poor countries, as well as the cost of needles and other supplies.”
“We’ve had a vaccine stored in a corn seed for five years without degradation,” he added.
Prodigene has two products about to go into clinical trials – a hepatitis B vaccine and one that fights the bacteria known as e. coli.
Ultimately, Rodemeyer said, “it’s hard to make predictions (about how beneficial this technology could be for the developing world). What’s important is do it in a safe, effective and affordable way.”